The role of exercise combined with tocilizumab in visceral and epicardial adipose tissue and gastric emptying rate in abdominally obese participants:Protocol for a randomised controlled trial by Christensen, Regitse Højgaard et al.
Syddansk Universitet
The role of exercise combined with tocilizumab in visceral and epicardial adipose
tissue and gastric emptying rate in abdominally obese participants
Protocol for a randomised controlled trial
Christensen, Regitse Højgaard; Wedell-Neergaard, Anne-Sophie; Lehrskov, Louise Lang;
Legård, Grit Elster; Dorph, Emma Berndt; Nymand, Stine; Ball, Maria Korf; Zacho, Morten ;
Christensen, Robin; Ellingsgaard, Helga; Rosenmeier, Jaya Birgitte; Krogh-Madsen, Rikke;
Pedersen, Bente Klarlund; Karstoft, Kristian
Published in:
Trials
DOI:
10.1186/s13063-018-2637-0
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY
Citation for pulished version (APA):
Christensen, R. H., Wedell-Neergaard, A. S., Lehrskov, L. L., Legård, G. E., Dorph, E. B., Nymand, S., ...
Karstoft, K. (2018). The role of exercise combined with tocilizumab in visceral and epicardial adipose tissue and
gastric emptying rate in abdominally obese participants: Protocol for a randomised controlled trial. Trials, 19,
[266]. DOI: 10.1186/s13063-018-2637-0
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 12. Jul. 2018
STUDY PROTOCOL Open Access
The role of exercise combined with
tocilizumab in visceral and epicardial
adipose tissue and gastric emptying rate in
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Abstract
Background: Exercise reduces the amount of visceral adipose tissue (VAT) and the risk of cardiometabolic diseases.
The underlying mechanisms responsible for these exercise-induced adaptations are unclear, but they may involve
lipolytic actions of interleukin-6 (IL-6). Contracting skeletal muscles secrete IL-6, leading to increased circulating IL-6
levels in response to exercise. The aim of this study is to investigate whether IL-6 is involved in mediating the
effects of exercise on visceral and epicardial adipose tissue volume and glycaemic control.
Methods/design: Seventy-five physically inactive males and females aged > 18 years with a waist-to-height ratio > 0.5
and/or waist circumference ≥ 88 cm (females) or ≥ 102 cm (males) are being recruited to participate in a 12-week
intervention study. Participants are randomly allocated to one of five groups (1:1:1:1:1). Two groups consist of
supervised endurance exercise training combined with the IL-6 blocker tocilizumab (ET) or saline used as placebo (EP),
two groups consist of no exercise combined with tocilizumab (NT) or placebo (NP), and one group consists of
resistance exercise and placebo (RP). Although the study is an exploratory trial, the primary outcome is change in VAT
volume from before to after intervention, with secondary outcomes being changes in (1) epicardial adipose tissue,
(2) pericardial adipose tissue and (3) gastric emptying. Depots of adipose tissue are quantitated by magnetic resonance
imaging Gastric emptying and glucose metabolism are assessed using mixed-meal tolerance tests.
Discussion: Understanding the role of IL-6 in mediating the effects of exercise on visceral and epicardial adipose tissue
and glycaemic control may lead to novel therapeutic approaches in the prevention of cardiometabolic diseases.
Trial registration: ClinicalTrials.gov, NCT02901496. Registered on 1 August 2016 and posted retrospectively on 15
September 2016.
Keywords: Visceral adipose tissue, Epicardial adipose tissue, Glucose homeostasis, Gastric emptying rate,
Interleukin-6, Exercise
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Background
Cardiometabolic diseases are a leading cause of death
worldwide and are becoming a dominant health problem
globally. Common pathogenic features shared by cardio-
metabolic diseases are visceral and cardiac adiposity,
low-grade inflammation and impaired glycaemic control
[1, 2]. It is well known that regular endurance exercise
reduces the volume of visceral adipose tissue (VAT) and
improves glycaemic control, and also overall lowers the
risk of cardiometabolic disease substantially [3–6].
The underlying mechanisms driving the exercise ef-
fects on VAT lipid metabolism are poorly understood,
but they may involve the cytokine interleukin-6 (IL-6).
During intensive exercise, skeletal muscles secrete IL-6
into the circulation [1, 7]. IL-6 has been identified as a
lipolytic agent, and a single infusion of recombinant
human IL-6 at physiological concentrations increases
lipolysis and fat oxidation in humans [8]. This finding
was replicated in vitro, with myotubes and adipocytes
increasing fat oxidation and lipolysis following IL-6
stimulation [8]. Whether the exercise-induced reduc-
tions in VAT are caused by the lipolytic effects of IL-6 or
other exercise factors is not known.
Whereas substantial evidence exists regarding the
training-induced reductions in VAT, the effect of exer-
cise on cardiac adipose tissue is poorly elucidated. One
study has shown that endurance exercise causes a reduc-
tion in epicardial adipose tissue thickness [9]. Yet, it is
unknown whether the exercise-mediated reduction in
visceral fat is equipotent in epi- and pericardial fat (EAT
and PAT, respectively). In addition, whether resistance
exercise can similarly reduce EAT and PAT volume is
unknown. Furthermore, whether the mechanism driving
the possible effects of exercise on EAT and PAT involves
IL-6 signalling remains to be investigated.
Despite an extensive amount of research on IL-6 in
rodents, it remains to be investigated how repetitive
systemic spikes of IL-6 (as seen with exercise) affect
glycaemic control in humans. On the basis of studies in
mice, it is known that IL-6 improves glucose tolerance
through a glucagon-like peptide-1 (GLP-1)-mediated
increase in insulin secretion [10]. In humans, an acute
increase in circulating IL-6 improves glycaemic control
by delaying the rate of gastric emptying (in press [11]).
In humans, gastric emptying rate is a critical regulator of
glycaemic control [12]. Yet, it remains to be investigated
whether repetitive systemic spikes of muscle-derived
IL-6 influence glycaemic control through changes in
gastric emptying rate.
Methods/design
Study hypotheses and aims
We hypothesise that endurance exercise plus saline
(placebo) is superior in mediating the reduction in
visceral, epi- and pericardial adiposity and is superior in
delaying gastric emptying compared with endurance
exercise plus tocilizumab (IL-6 blocking agent); that is, if
the null hypothesis is rejected and there is a difference
between the two endurance exercise groups, the alterna-
tive hypothesis might be true.
The primary aim of this study is to determine whether
blocking IL-6 signalling will ameliorate the endurance
exercise-mediated reductions in VAT volume. Secondary
aims are to investigate the importance of endurance
exercise-induced increases in IL-6 on EAT thickness/
area/volume, glucose homeostasis and gastric emptying.
Because it is not established if circulating levels of IL-6
are increased in response to resistance training [13, 14],
it was not within the scope of this study to include a re-
sistance exercise group receiving tocilizumab. However,
as a separate distinctive aim, the resistance exercise plus
placebo group was included to investigate the effects of
resistance exercise vs. endurance exercise on VAT, EAT
and glucose homeostasis.
Study design and study setting
The study is designed as an exploratory, double-blind, ran-
domised, placebo-controlled trial consisting of 12 weeks of
endurance exercise (E) or no exercise (N) combined with
monthly infusions of tocilizumab (T) or placebo (P), result-
ing in five groups (ET, EP, NT, NP and RP), where RP is a
placebo group using resistance exercise rather than endur-
ance exercise. A total of 75 physically inactive participants
are randomised in a ratio of 1:1:1:1:1 to exercise groups or
control groups in combination with tocilizumab or saline,
as depicted in Fig. 1. The enrolment period began on 1
August 2016 and was estimated to be completed by 26
April 2018. All baseline and follow-up tests are carried out
at the Centre for Physical Activity Research (CFAS),
Rigshospitalet, Copenhagen, Denmark, and the MRI depart-
ment of Frederiksberg Hospital, Frederiksberg, Denmark.
Participants
Eligibility
Participants are recruited through advertisements in
local newspapers and via social media. Eligibility criteria
are listed in Table 1. Initial inclusion and exclusion
criteria are identified through email and phone inter-
view. Participants are eligible if they are white, aged 18–
80 years, abdominally obese and physically inactive
(Table 1). Participants of same race are chosen in order
to limit the effect of racial background on lipid and glu-
cose metabolism [15]. The broad age span is chosen
because IL-6 response to exercise is not known to be
age-dependent [16, 17]. Abdominal obesity, which is
indicative of visceral adiposity, is defined as a waist
circumference > 88 cm for women or 102 cm for men
[18, 19]. Physical inactivity is defined as no engagement
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Fig. 1 Flow of participants through the study. Any reasons for discontinuation or exclusion from analysis are reported. ET (Endurance exercise +
tocilizumab), EP (Endurance exercise + saline (placebo)), RP (Resistance exercise + saline), NT (No-exercise control + tocilizumab), NP (No-exercise
control + saline)
Table 1 Eligibility of study participants
Inclusion criteria Exclusion criteria
1. Age 18–80 yr
2. White race
3. Physically inactive (defined as not meeting the current guidelines of
2.5 h of physical activity per wk)
4. Waist-to-height ratio ≥ 1:2 and/or waist circumference ≥ 88/102 cm
(for women/men)
5. Permitted medicine should be taken at a stable dose during at least
4 wk prior to randomization and preferably remaining stable during
the study.
1. Diabetes (HbA1c ≥ 48 mmol/mol or fasting glucose ≥ 7.0 mmol/L)
2. Pregnancy
3. Ischaemic heart disease
4. Atrial fibrillation
5. Treatment with:
a. NSAIDs on a daily basis
b. Biologic rheumatic drugs
c. Systemic prednisolone
d. Other immunotherapy
6. Health conditions that prevent individuals from participating in the
exercise training intervention
7. Subjects who cannot undergo MRI scans (e.g., owing to kidney disease,
metallic implants or claustrophobia)
Abbreviations: HbA1c Glycated haemoglobin, NSAIDs Non-steroidal anti-inflammatory drugs, MRI Magnetic resonance imaging
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in any intentional leisure exercise activities and failure to
meet the current American College of Sports Medicine
(ACSM) exercise guidelines of 2.5 h/wk [20, 21] by unin-
tentional physical activity associated with daily activities.
The unintentional daily activity level is evaluated indi-
vidually at the telephone screen by asking a number of
questions, including (1) type of occupation, which
should be sedentary (defined by primarily computer-
based activities [20, 22]); (2) way of commuting, which
should preferably be passive or alternatively biking at a
slow pace < 30 min/d on a maximum of 5 d/wk; and (3)
the total daily activity level assessed by steps per day
should be < 10,000, which is a reliable threshold for
meeting current activity guidelines [23]. If eligible after
the phone interview, the participant provides informed
oral and written consent and subsequently undergoes a
medical screening that includes blood sampling in order
to identify latent exclusion criteria.
Interventions
The intervention is a combination of two components: a
medical intervention (tocilizumab [T] or placebo [P])
and a lifestyle intervention (supervised exercise [E] or no
[N] exercise) as detailed below. The resulting interven-
tion and control groups are depicted in Fig. 1.
Medical intervention: IL-6 antagonism (tocilizumab)
Tocilizumab (RoActemra®; Roche, Basel, Switzerland) is
a humanised monoclonal antibody against the IL-6 re-
ceptor currently used for treatment of patients with
moderate to severe rheumatoid arthritis [24]. Partici-
pants will receive an intravenous infusion of 8 mg/kg
(maximal 800 mg) administered every 4 weeks during
the 12-week intervention (a total of three times) [25].
We chose to give the maximal recommended dose of
tocilizumab [24] because we aimed for maximal suppres-
sion of the effects of exercise-induced IL-6 secretion.
Tocilizumab is generally well tolerated. Serious adverse
reactions are rare but include infections and hypersensi-
tivity reactions. Tocilizumab is purchased via the phar-
macy at Rigshospitalet. It is prepared according to the
recommendation (8 mg/kg) and diluted in NaCl 0.9% to
a total volume of 100 ml. Qualified staff at CFAS are re-
sponsible for this procedure. The placebo consists of
100 ml of NaCl 0.9%. Both placebo and tocilizumab are
administered via intravenous infusion at a flow rate of
2 ml/min, and the infusion is concealed to maintain
double blinding.
Exercise intervention and lifestyle monitoring
The exercise programme includes three weekly training
sessions of 45 min/session over a 12-week period. Each
session will be moderate to vigorous in intensity. The
exercise programme follows current ACSM guidelines
for vigorous exercise [21] and was chosen because exer-
cise of similar intensity and duration is known to result in
IL-6 release [1, 17] and lead to changes in VAT (the
primary outcome) [13]. Training takes place at the Centre
for Physical Activity Research CFAS using TechnoGym
equipment (Pedan A/S, Copenhagen, Denmark) and soft-
ware programs which allow monitoring and registration of
all exercise sessions. All exercise sessions are supervised.
Maximal oxygen consumption rate (VO2 max) and one-
repetition maximum (RM) of two resistance exercises
(knee extension and chest press) are determined at base-
line and after the intervention for each participant. To
control for factors that may influence the effect of the in-
terventions, participants are instructed not to change their
lifestyle during the intervention, with the exception of the
intervention. A self-reported 3-day dietary intake record is
obtained monthly during the intervention period. Further-
more, free-living physical activity is measured monthly
using axial accelerometer-based physical activity monitors
(AX3; Axivity, Newcastle upon Tyne, UK) for a 4-day
period. The monthly registrations are undertaken in relation
to pre- and mid-testing as well as at post-testing on identical
visits and on identical consecutive weekdays throughout the
intervention to ensure comparable measurements.
Endurance exercise
High-intensity interval endurance exercise is performed on
an ergometer bike. The intensity of the intervals progres-
sively increases during the 12 weeks of training. The
45-minute exercise sessions consist of 8 minutes of warm-
up at 40% and 60% of VO2 max followed by 37 minutes of
interval exercise at 75–85% of VO2 max, as shown in Fig. 2.
Resistance exercise
The resistance exercise is matched to the endurance
training with a duration of 45 minutes per session. The
exercise is interval-type, medium-load, high-repetition,
time-based resistance exercise. Participants perform ten
exercises paired in five blocks. Three to five sets with ten
to fifteen repetitions lasting 1 minute are performed. The
aim is to reach complete exhaustion after each exercise.
The specific resistance exercise load comprises 60–80% of
1 RM with progression during the 12 weeks. Ten different
exercises are performed: shoulder press, leg extension, pull
exercise, crunches, leg press, shoulder laterals, chest press,
biceps, dumbbell squats and back extensions. Details of
the resistance exercise protocol are depicted in Fig. 3.
Outcomes
Outcome variables are listed in Table 2.
Primary outcome
The primary outcome is the change in volume of VAT
(measured using MRI) from baseline to after the 12-week
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intervention period, with comparison of the groups
(Fig. 1).
Secondary outcomes
The secondary outcomes are changes in (1) EAT, (2)
PAT and (3) gastric emptying. Also, we will explore the
effects related to the interventions in regard to changes
and alterations in rate of glucose homeostasis and low-
grade inflammation.
Measurement of outcome variables
The time points at which the outcomes are assessed at
baseline, during the intervention and at follow-up are
depicted in Fig. 4. The study is initiated with a clinical
examination followed by baseline testing (Fig. 4, visits
1–4). Monthly tocilizumab/saline (placebo) infusions
(Fig. 4, visits 4–6) are administered during the interven-
tion period. After the intervention period (12 weeks),
the participants undergo follow-up testing (Fig. 4, visits
7–10) identical to the baseline tests.
Blood samples
Following an overnight fast (10 hours), blood samples,
as specified in Fig. 4, are collected and processed by a
trained laboratory technician and analysed according to
standard procedures. Plasma is stored at − 80 °C prior
to analysis.
Abdominal and cardiac magnetic resonance imaging
MRI is performed at Frederiksberg Hospital using a
1.5-Tesla whole-body MRI scanner (Ingenia; Philips,
Eindhoven, the Netherlands). Abdominal MRI scans are
Fig. 2 Protocol of the endurance exercise. a Graphic demonstration of the different workload intervals of the endurance exercise programme.
The workload is defined by the corresponding maximal oxygen consumption rate (VO2 max) percentage. b Details of the exercise programme
a
b
Fig. 3 Overview of the resistance exercise protocol. a Progression in frequency of sets and repetitions during the 12-week exercise intervention
performed 3 × weekly. b The ten individual exercises that are paired in five blocks and performed in each resistance exercise session with a duration
of 45 min/session
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obtained as transverse images (slice thickness of 5 mm)
from the top of the thoracic diaphragm to the pelvic floor.
VAT will be manually marked on each image, capturing the
area from the diaphragm to the first sacral vertebra, and
the volume will be calculated as the sum of all voxels using
MANGO (Multi-Image Analysis GUI) version 2.5 [26, 27].
Cardiac MRI is supervised by a senior cardiologist, and
sagittal, axial and horizontal planes are obtained from five
retrospective cardiac cycles. Cardiac function including
myocardial mass is quantified using cine imaging with a
slice thickness of 8 mm (inter-slice gap, 2 mm for the
short-axis stack) and a temporal resolution of 30–50 milli-
seconds, depending on heart rate (25 acquired phases).
The number of short-axis cine images acquired is
participant-specific, depending on ventricular size, using
retrospective gating when possible in all participants.
Semi-automatic calculations using cardiovascular imaging
software (cvi42 version 5.2; Circle Cardiovascular Imaging,
Calgary, AB, Canada) will be used for post-processing
using endo- and epicardial contours to calculate left ven-
tricular ejection fraction and cardiac muscle mass. EAT
and PAT thicknesses, areas and volumes will be quanti-
fied from images in the end-diastolic four-chamber
view and short-axis view. Contours around the fat
layers of the ventricles and atria will be drawn manu-
ally. All MRI scans will be analysed in a blinded manner
by trained medical doctors. A subset of the cardiac
MRIs will be evaluated by a cardiologist to assess accur-
acy and inter-reader variability.
Maximal aerobic capacity
The participants undergo a graded exercise test on an
ergometer bicycle for determination of VO2 max. The
test starts with a 5-minute warm-up at 70 W. Warm-up
is immediately followed by a 15-W increase every mi-
nute until exhaustion. Ventilation rate and expired O2
and CO2 levels are measured via an indirect calorimetric
system, and heart rate is assessed simultaneously for the
duration of the test. Two separate VO2 max tests are
performed during the baseline tests (Fig. 4) to allow par-
ticipants to familiarise themselves with the bicycle and
the indirect calorimetric ventilation system. The test
with the best performance is used to assess the changes
in aerobic capacity from baseline to follow-up.
Body composition
Dual-energy x-ray absorptiometry is used to assess total
body fat mass and lean body mass one time before, two
times during and one time after the intervention.
Mixed-meal tolerance test
The mixed meal consists of a 350-ml liquid drink con-
taining 385 kcal. The energy distribution is 15% fat, 20%
protein and 65% carbohydrate (of which 9% is glucose).
To allow assessment of the rate of gastric emptying,
1.5-g paracetamol is dissolved and added to the meal
as a pharmacological tracer [28]. Participants are en-
couraged to ingest the meal in less than 2 minutes,
and serial blood samples will be drawn − 10, 0, 15,
30, 60, 90, 120, 150 and 180 minutes after intake of
the liquid meal. In addition to paracetamol, blood
samples will be analysed for glucagon, GLP-1, GIP,
PYY, insulin, pro-insulin, C-peptide and glucose.
Oral glucose tolerance test
A standard 2-hour 75-g oral glucose tolerance test is per-
formed following an overnight fast (10 hours). Blood sam-
ples are drawn at baseline (0), 15, 30, 60 and 90 minutes
and after 120 minutes, and then they are analysed for
glucose, insulin, and C-peptide.
Table 2 Outcome domains and measures assessed at baseline
and follow-up (12 weeks after baseline)
Outcome Domain Measurement
Primary Visceral fat tissue volume MRI
Secondary Epicardial adipose tissue
thickness/area/volume
Cardiac MRI
Pericardial adipose tissue
thickness/ area/volume
Gastric emptying rate
Cardiac MRI
MMTT and PCM
Other Total body fat mass DXA
Total body muscle mass DXA
Resting blood pressure BP monitor
Heart rate recovery Heart rate strap
Maximal aerobic capacity
(cardiovascular fitness)
VO2 max test
Muscle strength One-RM test
Diabetes, pre-diabetes
and glucose tolerance
OGTT
Glycaemic control during
mixed-meal tolerance test
MMTT
Free-living glycaemic
control
CGM
Acute exercise bouta Blood tests
Low-grade inflammationb Blood tests
Cardiometabolic
biomarkersc and
adipokines
Blood tests
Abbreviations: CGM Continuous glucose monitoring, DXA Dual-energy X-ray
absorptiometry, MMTT Mixed-meal tolerance test, MRI Magnetic resonance
imaging, OGTT Oral glucose tolerance test, PCM Paracetamol,
RM Repetition maximum
aBlood will be analysed for exercise factors, including interleukin-6, immune
cell counts and function, and biomarkers of low-grade inflammation
bBlood will be analysed for biomarkers of low-grade inflammation, including
high-sensitivity C-reactive protein, tumour necrosis factor-α, interferon-γ
and interleukins
cBlood will be analysed for cardiometabolic biomarkers, including total cholesterol,
high-density lipoprotein, low-density lipoprotein, glycated haemoglobin, fasting
insulin, fasting glucose and pro-brain natriuretic peptide
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Continuous glucose monitoring
Three days of continuous glucose monitoring (CGM) is
performed using enzyme-coated electrodes (iPro MMT-
7745WW; Medtronic, Northridge, CA, USA) placed
subcutaneously in the abdominal wall. For calibration of
the CGM system, finger-prick blood glucose measure-
ments are performed by the participant four times daily.
Acute bout of exercise
For the acute bout of exercise, participants perform a
45-minute exercise bout similar to an exercise session.
The workload is determined according to the latest
individual watt-VO2 relationship assessed during the pre-
and post-VO2 max test. Blood samples are drawn
prior to, during and after the exercise bout (baseline
and at 22, 45, 105 and 165 minutes) and analysed for
IL-6, immune cell count and function, and other
plasma biomarkers.
Statistical power and sample size considerations
For a two-sample pooled t test of a normal mean differ-
ence with a two-sided significance level of 0.05, assum-
ing a common SD of 265-g VAT, a sample size of 14 in
each group has a power of 82.2% to detect a difference
between the means − 300 and 0 g VAT in the endurance
exercise group + saline group (EP) and the endurance
exercise + tocilizumab group (ET), respectively. The ex-
pected change in VAT is based on unpublished data from
the CFAS. Fourteen participants will also be included in each
of the control groups (NT and NP) and the resistance exer-
cise + saline group (RP). Anticipating only a minor risk of at-
trition (over 12 weeks), a final sample size of 75 participants
will be included in the study (anticipating 15 in each group).
Analysis populations
This study (2TRAIN) primarily follows a per-protocol
design where participants are included in the analysis
Fig. 4 Time schedule of enrolment, interventions and assessments. Abbreviations: BMI Body mass index, BP Blood pressure, DXA Dual-energy X-ray
absorptiometry, ECG Electrocardiogram, MRI Magnetic resonance imaging, HC Hip circumference, VO2 max Maximal oxygen consumption rate, WC
Waist circumference, MMTT Mixed-meal tolerance test, OGTT Oral glucose tolerance test, RM Repetition maximum. 1Eligibility screen was conducted in
a telephone interview before study day 1. 2The exercise intervention is a 12-week supervised exercise programme with three sessions per week
consisting of either endurance or resistance exercise training. 3Blood samples will be drawn after an overnight fast (> 10 hours) and analysed for
haematologic, renal, endocrine, cardiac and hepatologic markers. Table is adapted from the SPIRIT recommendations [38]
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only if they have completed the trial and adhered to
tocilizumab/placebo combined with exercise/no-exercise
intervention according to the pre-specified protocol.
This design was chosen because we are interested in
measuring the physiological effect which is not influ-
enced by lack of adherence, unlike the intention-to-treat
(ITT) principle (with use of “conservative imputation”)
[29]. Using the per-protocol design enables us to assess
the true experimental effect of the medical and exercise
intervention on the primary endpoint [29]. Because non-
adherers generally differ from adherers with regard to
motivational and prognostic factors, this introduces a
bias in the per-protocol design. Yet, this bias is limited
because the aim of this study is exploratory, with the
aim of assessing the mechanism driving the exercise ef-
fects, which requires adherence rather than evaluation of
treatment efficacy where differential prognostic factors
would confound the effect measures.
Patterns of non-adherence and other missing data will
be investigated but will be assumed to be missing at ran-
dom. In case of high non-adherence, high drop-out rate
or skewed drop-out between intervention groups, a
third-party biostatistician will perform analyses that ad-
just for such instances. Satisfactory adherence is defined
as complete adherence to tocilizumab/placebo interven-
tion and a minimum of 80% adherence to the exercise
intervention/no-exercise control.
In addition, the ITT principle will be applied when ne-
cessary for the purpose of sensitivity analysis to assess
the robustness of the primary analyses where imputation
techniques (e.g., baseline observations carried forward)
will be used to replace missing data [30]. Any discrepan-
cies in data analysis between the methods will be re-
solved by a third-party biostatistician.
Statistical analyses and reporting
Like all clinical trials, exploratory studies should have clear
and precise objectives. However, in contrast to confirma-
tory trials, the objectives of the exploratory 2TRAIN trial
may not lead to simple tests of predefined hypotheses; that
is, we will apply a more flexible approach to the statistical
interpretation of the findings. As a consequence, a trial
such as 2TRAIN cannot be the basis of a formal proof of
efficacy, although it may contribute to the total body of
relevant physiological evidence.
The results will be reported in accordance with the
Consolidated Standards of Reporting Trials (CONSORT)
[31, 32]. Descriptive variables will be summarised by means
of frequency distributions, means and SDs, or medians and
IQRs, by group as well as by the total population. Categor-
ical data will be summarised by numbers and percentages.
The primary null hypothesis is based on the
comparison between participants randomised to endurance
exercise with (ET) or without (EP) tocilizumab; H0:
μET = μEP. The overall study design is based on five
groups (EP, ET, NT, NP and RP), and rather than looking
only at the two according to the primary objective, we
apply linear modelling based on generalised linear models
(GLMs) in the analysis of the primary outcome. Analysis
of covariance (ANCOVA) models will be performed,
which produces several diagnostic measures, provides
contrasts and estimates for customised hypothesis tests,
and it provides tests for means adjusted for covariates (e.g.
, least squares [LS] means adjusted for baseline variables).
The GLM procedure handles models relating a con-
tinuous dependent variable to one or several independent
variables. The independent variables can be either
classification variables, which divide the observations into
discrete groups (e.g., EP, ET, NT, NP and RP), or continu-
ous variables (e.g., the level at baseline). We will analyse
continuous outcomes using ANCOVA models, with a
fixed factor for group (five levels) and adjust for the value
at baseline. For each continuous outcome variable (after
performing the overall ANCOVA model [five-group
comparison]), we will obtain the P value and group con-
trast for the difference between the LS means: ET vs. EP
(in analogy to a two-sample t test [33]), independent of
what the overall ANCOVA model indicates. Also, results
following the ANCOVA model will be expressed as esti-
mates of the group difference in the various pairwise com-
parisons (including ET vs. EP) in the changes from
baseline, with 95% CIs to represent the precision of the es-
timates. To assess the adequacy of the linear models de-
scribing the observed data, as well as to check the
assumptions for the systematic and random parts of the
models, we will investigate the model features via the pre-
dicted values and the residuals; that is, the residuals have
to be normally distributed (around 0) and be independent
of the predicted values.
All reported P values will be two-sided and will not be
adjusted for multiple comparisons (despite having ten
potential tests for each outcome variable [5 × {5 − 1}/2]).
Per default, we set the statistical significance at the con-
ventional level of 0.05 (P < 0.05). All analyses will be per-
formed using commercially available statistical software.
Blinding
The primary investigators are blinded to intervention.
Outcome assessors are blinded to allocation at baseline
and follow-up. Owing to the nature of the study, partici-
pants cannot be blinded to the exercise modality, but
they are blinded to tocilizumab intervention. Interim
analyses are not performed.
Randomisation: sequence generation and allocation
concealment
Participants are randomly assigned to groups in a 1:1:1:
1:1 ratio using computer-generated block randomisation.
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Seven blocks of ten participants and a final block of five
participants were planned. In order to achieve a bal-
anced sample size of complete cases in each group,
drop-outs occurring in the first six blocks were replaced
in the subsequent block. If drop-outs are encountered in
the seventh and eighth blocks, these are not replaced.
The randomised sequence generation was generated by
a researcher who is not involved in the testing and was
delivered concealed to the technical personnel preparing
the infusions. Infusions are delivered to the study inves-
tigators in a concealed manner to maintain blinding.
The allocation information regarding exercise modality
is given to the participants by a study assistant not in-
volved in the randomisation or evaluation procedures.
Exercise sessions are supervised by educated study assis-
tants to maintain blinding of primary investigators with
regard to exercise modality.
Safety (based on collected adverse events)
Before every infusion of tocilizumab/placebo, partici-
pants undergo a clinical examination and an interview
performed by a medical doctor to assess health status,
followed by collection of a blood sample to detect any
adverse reactions (including drug-related side effects).
The following parameters are measured: alanine amino-
transferase, aspartate aminotransferase, creatinine, haemo-
globin, thrombocytes, glucose, total cholesterol, low-density
lipoprotein cholesterol, high-density lipoprotein cholesterol,
triglyceride, high-sensitivity C-reactive protein, leucocytes
and leucocyte types.
Intravenous infusion of gadolinium during cardiac
MRI scan can rarely cause adverse allergic reactions, but
the medical doctors present are educated to identify and
handle such situations. Rarely, infections or temporary
paraesthesias occur in the skin lesion that follows blood
sampling or muscle/fat biopsies. Participants are in-
formed about side effects and signs of infection. The
participants are urged to contact the medical doctors in-
volved in the trial at all times in case of an adverse reac-
tion or other symptoms experienced during the study
period. Any serious adverse event (life-threatening, fatal,
expected, unexpected, or drug-related) will be reported
to the scientific ethics committee at the Capital Region
of Denmark and, if requested, to the Danish Medicines
Agency.
Discussion
In this study, we are investigating the role of IL-6 in me-
diating exercise-induced adaptations in an abdominally
overweight population. We anticipate the results to pro-
vide insight into the role of IL-6 in exercise-mediated
changes in VAT, EAT and PAT and glucose homeostasis.
Furthermore, we hope to gain valuable insight related to
the exercise modalities that can be translated into
efficient exercise programmes for subjects with in-
creased risk for metabolic diseases. Understanding how
exercise and IL-6 regulate VAT, EAT and PAT volumes
and glucose homeostasis may inform novel therapeutic
approaches in the prevention and treatment of cardio-
metabolic diseases.
The study is a randomised controlled trial, and both
participants and primary investigators are blinded with
respect to the medical intervention of tocilizumab and
the outcome assessments. It is not possible to blind par-
ticipants with respect to the exercise intervention, and
this may introduce a bias. To limit this bias, participants
are urged not to change their lifestyle during the inter-
vention, except from what they are randomised to, be-
cause this would potentially influence the outcomes of
the intervention. The eating habits and activity levels of
the participants are regularly assessed by use of dietary
records and axial accelerometer-based physical activity
monitors. It is important to acknowledge that the resist-
ance and endurance exercise protocols are matched only
in duration. This is a limitation which should be kept in
mind when interpreting the effects of the different exer-
cise modalities. To compare the intensity of the different
exercise modalities, we ask the participants to wear a
heart rate monitor during both resistance and endurance
exercise sessions. Exercise intensity is determined by
percentage of VO2 max, and not by the peak power out-
put, in line with previous studies by our group [34, 35].
Helgerud et al. [36] previously showed VO2 max to in-
crease in response to high-intensity interval exercise
training. Therefore, we believe that adjustment of exer-
cise intensity according to percentage of VO2 max ac-
curately ensures high exercise intensities throughout the
intervention in this study. In addition, the supervised
nature of the exercise protocol will ensure participant
adherence and intensity and thereby improve the homo-
geneity of each intervention. The measurement of the
primary outcome by MRI follows the gold standard and
will enable accurate estimations of changes in the VAT,
EAT and PAT depots.
The study includes five intervention groups (ET, EP,
NT, NP and RP), and the endurance exercise groups
with and without tocilizumab (ET vs. EP) are of primary
interest. In order to control for isolated effects of toci-
lizumab, two no-exercise control groups (NT and NP)
were included as well. The inclusion of a resistance exer-
cise group without tocilizumab (RP) was intended only
for future ad hoc objectives, including comparisons of
exercise modalities (endurance vs. resistance exercise
without tocilizumab) on changes in VAT, EAT, PAT and
gastric emptying.
This study is conducted in accordance with the guide-
lines of the regional ethics committee and the Declaration
of Helsinki II [37]. All participants receive written and oral
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information about the study prior to inclusion and their
provision of oral and written consent. The participants
can discontinue participation in the study at all times with
no obligation to provide a reason. Data and associated
biological material are stored in an individual database
and research biobank at Rigshospitalet. The biological
material will be destroyed after a maximum of 10 years.
Confidentiality of the participants is maintained by assign-
ing participants a study number, keeping identifiers separ-
ate from the data, and storing data in a locked file and
secure computer database. Scientific reports generated
from the study will not contain information that would
identify the participants.
The study protocol adheres to the Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT)
guidelines [38] (Additional file 1), and results of this study
will be reported according to the CONSORT guidelines
[31]. Negative, positive or inconclusive results will be dis-
seminated in international peer-reviewed scientific jour-
nals at national and international conferences.
Trial status
The study was prospectively registered at ClinicalTrials.gov
(NCT02901496) on 1 August 2016 and posted retrospect-
ively on 15 September 2016. The recruitment period began
on 1 August 2016 and was estimated to be completed
by 26 April 2018.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 131 kb)
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